DB
Therapeutic Areas
Chimeric Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CHM CDH17 CAR‑T | Gastric, neuroendocrine, and colorectal cancers | Phase 1/2 |
| CHM CLTX CAR‑T | Solid tumors (specific indications not disclosed) | Phase 1/2 |
| CHM CORE‑NK | Acute myeloid leukemia, other blood cancers, colorectal cancer | Phase 1b |
Leadership Team at Chimeric Therapeutics
DR
Dr Rebecca McQualter
Chief Executive Officer
DS
Dr Stephanie H Astrow
Chief Scientific Officer
DA
Dr Agathe Bourgogne
Head of Manufacturing
PH
Philip Hains
Non‑Executive Director
DL
Dr Lesley Russel
Non‑Executive Director
ES
Eric Sullivan, CPA
Non‑Executive Director
PM
Prof Miles Prince
Non‑Executive Director